Featured Story

Preclinical study advances H. pylori vaccine for stomach cancer

Researchers are one step closer to creating a human vaccine for Helicobacter pylori, a bacterium found in 50% of the world's population that infects the stomach and causes chronic gastric inflammation, which can lead to ulcers and stomach cancer.

Single molecule that targets both amyloid and tau could treat Alzheimer's

The Alzheimer's research field has been marked by one failure after another in pursuit of effective treatments, but Cambridge, MA-based NeuroPhage Pharmaceuticals thinks it can tackle the devastating disease with a novel approach.

Experimental drug could thwart measles outbreaks

A new antiviral drug may provide an effective way to treat measles in those who have not been vaccinated.

Mouse model could have predicted drug toxicity that killed 5 in clinical trial

In a 1993 clinical trial of fialuridine--a drug originally designed as a therapy for hepatitis B--5 out of 15 patients died from sudden liver failure. A new study in PLOS Medicine found that mice with humanized livers demonstrate the drug's toxicity.

Improved monitoring of zoonotic diseases could predict future Ebola outbreaks

The ongoing Ebola outbreak in Western Africa underscores the critical need for better global surveillance strategies to combat the emergence of infectious diseases, especially those that have high mortality rates and pose a bioterror threat to countries, according to a new study.


From Our Sister Sites


Going well beyond the standard sponsor-CRO relationship, Biogen Idec has recruited Quintiles to revamp its clinical development process, giving the contractor a seat at the R&D table to improve trial efficiency.


With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship it already has with South Korea's Samsung BioLogics.